文献速递肾小球疾病

Sibeprenlimab治疗IgA肾病期间对COVID-19疫苗和感染的体液反应:ENVISION试验数据

Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-06-11

ENVISION 2期试验的探索性亚组分析评估了sibeprenlimab对IgA肾病患者COVID-19疫苗和感染体液反应的影响。结果显示sibeprenlimab治疗降低致病性IgA,同时保留对COVID-19疫苗和感染的保护性体液反应,症状性COVID-19发生率组间相当(33.3% vs 44.7%)。

要点

  • sibeprenlimab降低致病性IgA,不增加症状性COVID-19感染风险。
  • 疫苗接种或感染后IgG-RBD血清转化率100%,抗体反应保留。
  • 未观察到B细胞或T细胞有意义扰动,提示免疫抑制风险较低。

核心结论

  • sibeprenlimab抑制APRIL降低致病性IgA,同时保留黏膜免疫和针对COVID-19疫苗和感染的系统抗体反应。

研究设计与样本

  • 2期ENVISION试验(NCT04287985)的探索性亚组分析,155例参与者中72例(sibeprenlimab组52例,安慰剂组20例)同意参加亚组研究。
  • 参与者接受12次每月静脉输注sibeprenlimab(2、4或8 mg/kg)或安慰剂。

主要发现

  • 症状性COVID-19发生率组间相当:sibeprenlimab组33.3%,安慰剂组44.7%。
  • 疫苗接种或感染后SARS-CoV-2 RBD IgG血清转化率为100%。
  • 所有COVID-19未暴露的sibeprenlimab受者接种mRNA疫苗后IgG-RBD峰值滴度超过保护阈值,且IgG-RBD持久性与安慰剂组相当。
  • 感染后COVID-19特异性IgG、IgA和IgM抗体反应保留,唾液中检测到IgA-RBD反应提示黏膜免疫保留。
  • 未观察到B细胞或T细胞的有意义扰动。

临床怎么用

  • sibeprenlimab治疗期间可能无需担心对COVID-19疫苗或感染抗体反应的显著抑制。

局限性

  • 亚组研究的样本量小和探索性设计妨碍确定性结论,需要进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: The phase 2 ENVISION trial evaluated efficacy and safety of intravenous sibeprenlimab, a selective A PRoliferation-Inducing Ligand inhibitor. Because the trial was conducted during the coronavirus disease 2019 pandemic, we assessed if sibeprenlimab affected humoral responses to coronavirus disease 2019 infection or vaccine. Sibeprenlimab treatment resulted in reduced pathogenic IgA and preserved protective humoral response to coronavirus disease 2019 vaccine and infection. BACKGROUND: In phase 2 ENVISION trial, sibeprenlimab, a selective A PRoliferation-Inducing Ligand inhibitor, significantly decreased proteinuria and stabilized eGFR in adults with IgA nephropathy. This exploratory substudy evaluated coronavirus disease 2019 (COVID-19) severity, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses to vaccine and infection, and circulating B-cell populations in patients with IgA nephropathy treated with sibeprenlimab or placebo. METHODS: Participants enrolled in ENVISION ( NCT04287985 ) received 12 monthly intravenous infusions of sibeprenlimab (2, 4, or 8 mg/kg) or placebo. COVID-19 infection and vaccination data were recorded for all participants. In a substudy, serum IgG responses to SARS-CoV-2 spike protein, its receptor binding domain (RBD), and nucleocapsid antigen were assessed, with further analysis of serum IgM and IgA and salivary IgA against RBD in a subset of participants. Circulating T cells and B-cell subsets were analyzed by flow cytometry. RESULTS: Overall, symptomatic COVID-19 incidence was comparable between groups (33.3% sibeprenlimab versus 44.7% placebo), indicating no observable excess risk of COVID-19 infection with sibeprenlimab. Of 155 participants, 72 (sibeprenlimab n =52; placebo n =20) consented to the substudy. Within the substudy, COVID-19 seroconversion rates were 100% for IgG against SARS-CoV-2 RBD (IgG-RBD) after vaccination or infection. Peak IgG-RBD titers after mRNA vaccination exceeded protective thresholds in all COVID-19-naive sibeprenlimab recipients, and IgG-RBD durability was comparable between sibeprenlimab and placebo. COVID-19-specific IgG, IgA, and IgM antibody responses to infection were preserved, and IgA-RBD responses detected in saliva suggested preservation of mucosal immunity with sibeprenlimab. No meaningful perturbations in B or T cells were observed. CONCLUSIONS: A PRoliferation-Inducing Ligand inhibition with sibeprenlimab reduced pathogenic IgA while preserving mucosal immunity and systemic antibody responses to COVID-19 vaccination and infection. The absence of B-cell perturbations and the apparent absence of an increased risk of impaired vaccine response suggest that sibeprenlimab may not confer clinically significant immunosuppressive risks; the substudy's size and exploratory design preclude definitive conclusions, warranting further evaluation. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT04287985 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. McCafferty K, Barratt J, Suzuki Y, et al. Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial. Clin J Am Soc Nephrol. 2026. PMID: 42275148. doi:10.2215/CJN.0000001089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。